Study of NAV-240 in Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The primary purpose of this study is to evaluate the safety and tolerability of intravenous (IV) doses of NAV-240 in healthy volunteers.

Key facts

Study ID

NCT06181786

Run by

Navigator Medicines, Inc.

People needed

40

Starts

2023-11-22

Expected to finish

2024-09-04

Last updated by the study team

2025-06-17

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

• Syneos Health — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.